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ABSTRACT
COMPARISON OF 3D BIO-PRINTED IPSC-CMS DERIVED FROM HEALTHY
DONORS AND PATIENTS WITH HLHS
Wei He
Marquette University, 2022
Hypoplastic left heart syndrome (HLHS) is an extremely severe form of
congenital heart disease, but current treatments are not adequate. In order to find more
effective treatments, we need to reproduce in vitro the physiological characteristics of
cardiomyocytes associated with HLHS. Such a tissue model could be of great help to
current medical research, and 3D printing technology is an effective tool for this
purpose. We print layer-by-layer cardiomyocytes from both healthy and HLHS patients
with laminin-based bioink to form a three-dimensional model. With our 3D cell culture
technology, this model can simulate the growth conditions of cardiomyocytes in vivo.
Measurements of the 3D printed samples at different time points showed that our model
was able to fully demonstrate the differences between healthy and HLHS patients'
cardiomyocytes. This result is the basis for more studies in the future, and we hope to
build on this foundation with more diverse tests, such as drug tests, which will provide
important help in the treatment of HLHS.
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1. Introduction
Hypoplastic left heart syndrome (HLHS) is a complex congenital heart disease
(CHD) that often results in severe underdevelopment of the left side of the heart. It
can affect the left ventricle, aorta, aortic valve, or mitral valve. This disease accounts
for most of the CHD mortality (Barron et al., 2009).
The most common treatment for hypoplastic left heart syndrome is "staged
reconstruction" in which a series of procedures (usually three) is performed to
reconfigure the child's cardiovascular system. The first stage is the Norwood
procedure performed at birth; the second stage, the bi-directional Glenn procedure, is
performed when the patient is 6 to 8 months old. The last stage, the Fontan procedure,
is usually performed when the patient is 18 months to 4 years old (Best et al., 2021).
This series is accompanied by a high level of risk, with the highest mortality rate
being the initial procedure, with as many as three out of ten patients dying in some
reported cases (Tabbutt et al., 2005). Patients who survive a complete reconstruction
may also suffer from complications such as renal dysfunction, liver abnormalities, and
abnormal heart rates (Feinstein et al., 2012).
Another major treatment is cardiac transplantation. However, this approach is
less popular because of the scarcity of donor organs in newborns and because it has a
higher mortality rate than staged reconstruction.
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An in vitro disease model is important for the discovery and development of
therapeutics, 3D bioprinting technology offers a way to build complex living tissues
and organs. 3D printing is an important and emerging innovative technology that is
widely used in industry, manufacturing, medicine and other fields. While traditional
2D printing is only on a flat surface, 3D printing not only gives shape to the material
being printed but also allows precise control of the internal structure of the printed
object. Bioink mixed with cells can be printed layer by layer, the same way cells are
layered within tissues and organs in the human body. Many studies have begun to use
this technique to construct pathological models of CHD, such as the bioengineered
functional heart tissue with similar properties to natural heart tissue constructed by
Zhan et al. using primary cardiomyocytes isolated from young rat hearts by 3D
printing (Wang et al., 2018a).
Compared to their study, we use human induced pluripotent stem cells derived
cardiomyocytes (iPSC-CMs) instead of animal cells, which makes our study more
groundbreaking and innovative. iPSCs are human somatic cells that have pluripotency
by reprogramming the ectopic expression of transcription factors (Park et al., 2008).
iPSCs can differentiate into different cell types such as cardiomyocytes. iPSC-CMs
can theoretically differentiate into the cells we need indefinitely, since the origin of
these cells is often the skin or a small fraction of the blood and iPSC-CMs can show
structural and regulatory elements present in a human CM, and basic functional
properties of the human heart (Karakikes et al., 2015), and the genome they carry.
Thus iPSC-CMs have now become an important basis for cardiovascular research.
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It has been shown that cardiomyocytes differentiated from iPSC of HLHS
patients can exhibit developmental and functional defects in vitro in culture, and that
the gene expression causing these defects can persist in these cardiomyocytes. This
supports our choice of iPSC-CM to mimic the developmental process of the hearts of
HLHS patients (Jiang et al., 2014).
Cardiomyocytes grow in the human body in an environment that is not
dimensionally limited, specifically, cardiomyocytes can interact with their
surroundings and other cells during their development in the human body. Traditional
2D plate culture is the dominant way to culture cells in vitro, but 2D plate culture
leads to two-dimensional monolayers of cells, loss of cellular interactions, and shape
changes that affect gene and protein expression, and therefore, cells function
differently. And we introduce 3D cell culture technology to provide a suitable
microenvironment for the development of printed heart tissue. 3D cell culture systems
can mimic the in vivo environment and show the cell development process
(Edmondson et al., 2014a). In 3D cell culture, cells are closer to living tissues in terms
of biological structure and bio-functional properties than in traditional 2D flat cell
culture (Duval et al., 2017a).
In this study, we aim to construct a model that can restore cardiomyocytes in
the human developmental environment and using this model we will perform a series
of tests to compare the differences between bio-printed iPSC-CMs from healthy
donors and HLHS patients. Thus, to further understand the etiology of HLHS patients
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and the process of defective cardiomyocyte development, we hope to find inspiration
in this study that will help treat or alleviate this disease.
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2. Materials and methods

2.1 Bioprinter and bioink
The 3D printer (Fig.1) we use is an extrusion type commercial printer (Cellink
Inkredible+). This is a common and affordable printer that has the advantage of being
able to print very high-density constructs (Murphy & Atala, 2014). Extrusion printers
have high compatibility in the use of bioinks, including hydrogels, microcarriers, etc.
(Ozbolat & Hospodiuk, 2016). The disadvantages are the low precision and the
shearing force during the printing process can break the bioink connection, but this
can be restored by crosslinking the constructs after printing (GhavamiNejad et al.,
2020).

Fig.1 The bioprinter used in the experiment consists of a printer body (Left)
and an air pump (Right).
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2.2 Preparation of the mixture of cells
There were two sets of samples in our study, one set of tissues printed from
iPSC-CMs of healthy donors called wild type, and the other set of the mixed type
made from iPSC-CMs of healthy donors and iPSC-CMs of patients with HLHS in a
1:1 ratio. iPSC-CMs that had been differentiated for 15 days were washed with PBS.
Cells were pre-digested with 0.25% trypsin and incubated at 37°C for 10 minutes.
Cells were then collected and mixed after adding double the amount of RPMI/20%
FBS solution. The mixture was centrifuged at 1000 rpm for 5 min, the supernatant
was aspirated, and the cell pellet was resuspended in 0.2 ml of culture medium. 1μl of
5 μM Rock inhibitor was added to the cells and then the cells were mixed with bioink.
After centrifugation for 5 min, the mixture of cells and bioink was placed in warm
beads at 37°C and awaited printing.
The number of cells per print was about 1.61×108 and the solution volume of
bioink and cells was about 1.5 ml (0.3 ml for cells and 1.2 ml for ink). Cell density is
also one of the key factors in determining the success of printing. Too large a density
will result in poor ink flow and printed constructs with missing shapes; too small a
density will result in printed constructs with little cell content, making it difficult for
the constructs to contract as a whole in subsequent cultures. After a number of
experiments, we found that the density we were currently using was more suitable,
and the printed constructs could maintain their shapes while there were a large
number of cells in the constructs, and the constructs appeared to be beating as a whole
within a week after printing.
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2.3 3D bioprinting
The bioprinter was turned on and the printhead was preheated to 25°C. After
first zeroing the printhead pressure, the holder was calibrated — the calibration
syringe was placed into the holder and the axes were initialized, after which the
holder could be set to the height we designed. To ensure that the ink was still warm,
the above preparations should be done before the ink was ready.
Place the ink-filled syringe in the holder for 10 minutes to allow the 37°C to
drop to 25°C because the printhead would only start working once it had reached the
temperature we had set. Adjust the pressure on the printhead until the ink flowed
smoothly, then select the code we programmed earlier and the bioprinter would start
the printing job. The ink was extruded from the printhead and a 3-layer cube was
printed on the culture plate with a volume of 4 mm × 4 mm × 0.6 mm (Fig.2). The
code was set to print 4 plates at a time with a 15-second interval between plates and
UV light would crosslink the printed construct during the interval. When printing was
complete, the plates were sent to the cell culture hood for the next step.
During the printing process we encountered a variety of problems including
the adjustment of air pump pressure, air bubbles created when the ink mixed with the
cells, printing for too long resulting in lower ink temperature, etc. These problems
caused our printed constructs to be too small (Fig.3) or to have a missing shape
(Fig.4). We concluded the solution after several attempts, first we determined the
approximate pressure range of 18-30 kPa and then adjusted the pressure in real time
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during the printing process according to the ink flow rate and the shape of the printed
constructs. Air bubbles in the ink had been our most troubling problem, cells and ink
mixing in order to ensure uniform distribution within the solution needed to be
repeatedly squeezed back and forth in two syringes, this situation was difficult to
avoid the generation of air bubbles, we could only use centrifugation to reduce the
impact of air bubbles. Although the printhead of the bioprinter could set the
temperature, but the ink was not heated when passing through the needle, our printing
was carried out in a room temperature environment, so in the case of low room
temperature and long period of printing would occur in the ink cooling resulting in the
needle was blocked. Our solution was to replace the needle after a round or two of
printing to ensure that the ink could flow smoothly.
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Fig.2 The constructs after one round of four prints, each construct is basically
a cube.

Fig.3 The red circle shows an irregularly shaped and apparently small
construct.
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Fig.4 A near-rectangular but slightly notched construct is shown in the red
circle.

2.4 Crosslinking after 3D printing
Crosslinking plays an important role in 3D cell culture. During the
crosslinking process, the cells in the printed constructs are more tightly connected and
the density is enhanced therefore providing greater stability (Reddy et al., 2015). In
our experience, if a construct is not fully crosslinked, it adheres to the bottom of the
plate. The shape of some structures is disrupted and the cells are scattered (Fig.5). In
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this case, the construct can hardly be considered "three-dimensional”, and the tissue
can hardly contract even after a long period of culture. The advantages of UV light as
a commonly used means of crosslinking are ease of handling and lower cost.
However, if the printed construct is exposed to UV light for a long time it can cause
damage to the DNA of the cardiomyocytes (Derakhshanfar et al., 2018). To reduce
damage to the cells we controlled the duration of UV (405 nm) irradiation to 15
seconds, and to ensure complete crosslinking of the printed constructs, we added
another crosslinking agent (CaCl2 solution) on top of the UV crosslinking. Studies
have shown that bioink containing calcium ions improve biological viability (Gao et
al., 2017).
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Fig.5 The figure shows a poorly crosslinked construct with cells scattered and
adhering to the bottom of the plate.

2.5 3D cell culture
After soaking with CaCl2 solution, the constructs were washed with PBS, and
then the medium were added to the plates. We used RPMI medium with B-27
supplementation, 20% fetal bovine serum and 1× antibiotic-antimycotic. RPMI
medium supports the differentiation of iPSC into cardiomyocytes, although other
media such as DMEM and MEM can also promote the differentiation of
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cardiomyocytes, but RPMI is more effective than these media (Lian et al., 2015). All
plates were placed in a 37°C incubator and the medium were changed every three
days for each plate. Despite the addition of antibiotic-antimycotic to our culture
media, contamination (Fig.6) is difficult to avoid during longer culture periods, as we
need to remove samples from the incubator daily for observation. Even though we
have tried to avoid contamination, there are still many contaminations that make our
samples are impossible to use for measurement.
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Fig.6 The figure shows a contaminated plate. It is difficult to save cells from
contamination, and once contamination is present in a plate it is impossible to be used
for subsequent measurements. Moreover, one plate can contaminate other plates
nearby overnight and we have to clean the whole incubator, which affects the progress
of the whole experiment.

2.6 Observation and recording
Each sample was observed and recorded under the microscope daily. The
microscope eyepiece was 10× and photographs and videos were taken under
objectives 4×, 10×, and 20× (only the 100× videos were used to analyze). The video
format was 2880×2600 with 5 frames per second. The photo format was 2880×2200,
and a scale bar was set up in the photos. Photographs and videos taken on the same
day belonging to the same sample were used to calculate the contraction velocity and
displacement of the bio-printed tissue at the point in time we had set (every 5 days).
Photographs with scale bar were imported into ImageJ to calculate the pixel length
scale, which was used to calculate the pixel displacement distance in the video
analysis program.
We used a MATLAB program (Shradhanjali et al., 2019) for video analysis to
measure the displacement of tissue due to contraction in the video. The program
would automatically calculate the displacement of the pixels in each frame and obtain
the maximal averaged displacement based on the average of the displacements of all
pixels. Also since the video is 5 frames per second and the timestep of a frame is 0.2
seconds, dividing the maximal averaged displacement by 0.2 will give the maximal
averaged contraction velocity.
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The program utilizes the Adaptive Reference-Digital image correlation (ARDIC) method to continuously adjust the adaptive reference frame so that the
displacement occurring during the spontaneous contraction of the cardiomyocyte is
correctly quantified. Shown in Fig.7 (a) is a frame from a video (video taken under a
microscope at 100× magnification) of the contraction of the 3D printed construct, and
in Fig.7 (b) is a pixel map of the contracted construct captured by the program using
AR-DIC. The program compared all the displacements of each pixel point from the
initial position to the one produced by the construct contraction, then selected the
maximal displacement of each pixel point from all the displacements and divided the
maximal displacement of all the pixel points by the number of all the pixel points
after accumulating them to obtain the maximal averaged displacement.

16

Fig.7 The maximal averaged displacement resulting from the contraction of
the construct was analyzed using the MATLAB program. (a) A frame from a video of
the contraction of the wild type after 20 days of culture (video taken under a
microscope at 100× magnification); (b) pixel map of the contracted construct captured
using the AR-DIC method of the program.
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2.7 Immunofluorescence
The sample collection time points established for our study were days 5, 10,
20, and 30 (after printing), and when this time point was reached, samples with less
contraction among wild type and mixed type were selected for the collection. We did
this because in our experience samples that contract less or even stop contracting had
often begun to apoptosis and would not return to viability even if the tissue continued
to be cultured. To ensure that there were still samples that were still contracting at
subsequent time points, we must prioritize the collection of less viable samples.
The collected samples were fixed by aspirating the culture solution and rinsing
three times with PBS solution, adding 4% PFA solution, and shaking at -4°C for 15
minutes. The samples were then permeabilized by adding a mixture (primary antibody
solution) of GATA4, α -actinin, and PBS (1:400 for GATA4 and 1:250 for α -actinin)
and shaken overnight at 4°C. After removing the primary antibody solution and
rinsing five times with PBS, the secondary antibody solution was added and shaken
for one hour at room temperature, with the primary components of 2° GATA4
(donkey anti-Rabbit Alexa Fluor 594), 2° α -actinin (goat anti-Mouse IgG1 Alexa
Fluor 488), DAPI and PBS. The ratio of all three secondary antibodies was 1:750.
After thoroughly washing off the secondary antibodies with PBS solution, the samples
were mounted on coverslips with Prolong Gold Antifade Reagent (Molecular
ProbesTM).
Samples were photographed at 630× magnification (Fig.8) under a confocal
microscope (Zeiss). The resolution of the photo with the scale bar is 673×673. Import
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the image with the scale bar into ImageJ and measure the length of each pixel with the
scale length. As shown in the figure below, drag and drop the image you want to
measure into ImageJ, select 'Straight' in the toolbar, then enlarge the scale as shown in
Fig.9 (b) and draw a horizontal line from the head to the end of the scale bar with the
mouse pointer. Then go back to the toolbar and select 'Analyze' and select 'Set Scale'
in the drop-down menu. At this point, ImageJ will pop up the same interface as Fig.9
(c), 'Distance in pixels' indicates the length of the drawn line in pixels. In the 'Known
distance' column, fill in the actual length of the scale bar, and then change the units in
the 'Unit of length' column to the units of the scale bar. The 'Scale:' column below
shows the conversion relationship between the pixel length and the actual length in
this image. For example, Fig.9 (c) shows 16.2 pixels/μm, which means that one
micron is equal to 16.2 pixels in this image. In other words, the actual length of one
pixel is about 0.062 microns.
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Fig.8 Pictures taken after immunization fluorescence under a confocal
microscope at 630× magnification. Red, GATA4. Green, α-actinin. Blue, DAPI.
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Fig.9 Measure the actual length of pixels in an image using ImageJ. (a) image
after immunofluorescence of wild type after 10 days of culture (image taken under a
confocal microscope at 630× magnification) with a scale bar length of 5 µm; (b)
select 'Straight' in ImageJ and draw a horizontal line on the magnified scale bar; (c)
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select 'Analyze' and 'Set Scale' in the toolbar and enter the actual length and unit of
the scale bar, which is converted to obtain the length of individual pixel of the image.

Import the image with scale bar into ZEN software (3.4, blue edition), frame
the area of interest (perpendicular to the direction of the sarcomere alignment) and the
software will export the densities between each sarcomere (in pixels). Multiply the
pixel length by the ratio derived with ImageJ to get the sarcomere length. The lengths
obtained for multiple photos belonging to the same sample were averaged for
comparison in this study.
As shown below (Fig.10), drag and drop the same image which derived actual
pixel length using ImageJ into ZEN, select 'Profile' in the left toolbar, and then select
the Rectangle tool in the bottom toolbar. Zoom in on the area you want to measure in
the image bar, draw a rectangle in the area, and note that the center line of the
rectangle needs to be perpendicular to the direction of the sarcomere alignment
(Fig.10 (c)). The tool will automatically check the intensities of each sarcomere
within the rectangle and display them in summary on the left side of the image (Fig.10
(b)). Since we are using the trial version, we need to manually calculate the pixel
distance between each peak of the left image and multiply it by the ratio derived with
ImageJ to get the actual sarcomere length.
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Fig.10 Calculate the sarcomere length using ZEN software. (a) The interface
of ZEN software; (b) The image on the left side at the top of the interface,
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summarizing the intensities of the sarcomeres within the rectangle tool, calculating
the pixel distance between each peak and multiplying it by the actual pixel length
derived previously to obtain the sarcomere length;(c) Zoom in on the area of interest
with the center line of the rectangle tool perpendicular to the direction of the
sarcomere alignment.

The resolution of the images without scale is 2048×2048 and these photos
were used to analyze the organization index. We chose to use the organization index
to quantify the alignment of sarcomeres in the samples.
This is done by importing the original color image into ImageJ, separating the
colors (Fig.11 (a)), and converting the image with sarcomeres to binary (Fig.11 (b)).
Select 'Grid' in the toolbar (Fig.11 (c), for our experiments we chose the default size
(Fig.11 (f)). Using the grid as a unit, zoom in on the grid (Fig.11 (d)) you want to
measure and use the 'Straight' tool to draw a straight line through the sarcomeres.
Hold down the 'ctrl' and 'K' keys on the keyboard at the same time to get the
distribution of the intensities of the sarcomeres in the grid (Fig.11 (e)) and import the
data into the MATLAB program to get the sarcomere organization index in the grid.
The global organization index can be calculated by importing the data of multiple
grids into the program at the same time (Fig.11 (g)), and then the organization index
of multiple images of the same sample can be averaged to obtain the organization
index of the sample.
The organization index of the image was obtained by measuring the intensities
of the sarcomeres in each grid and then using MATLAB to perform FFT (Hinson et
al., 2015) on the intensities. The organization index of multiple images belonging to
the same sample was averaged, and then the organization index of all samples was
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then listed together, and all values are normalized by the maximum value (Deacon et
al., 2019).
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Fig.11 Calculation of sarcomere organization index using ImageJ and
MATLAB. (a) Color differentiate the colored images (similar to Fig.8) to keep only
the parts containing sarcomeres; (b) Binary conversion of the resulting image; (c) Lay
the grid on the converted image, we use the default size grid (f); (d) Using the
'straight' tool to draw a straight line through the sarcomeres in the grid where the
measurement is desired; (e) Hold 'ctrl' + 'K' to obtain the distribution of sarcomeres
intensities within that grid; (g) Repeat steps (c), (d) and (e) to get the data of
intensities distribution of all grids of the image and import into MATLAB to get the
organization index of the image.

2.8 RT-qPCR
The sample collection time points were the same as the immunofluorescence.
Two samples from each group were picked, the medium was washed off with PBS
and stored at -80 degrees Celsius. We purified the samples with RNeasy Plus Micro
Kit (Qiagen).
We used 1.0 µg of total RNA for cDNA synthesis (Qiagen QuantiTect RT Kit).
Thaw all reagents on ice and flick each tube to mix. Quickly centrifuge all reagents to
bring the residue to the bottom of the tube. Prepare the gDNA elimination reaction on
ice, then incubate at 42 degrees C for 2 minutes and immediately place on ice. Prepare
the reverse transcription master mix for each tube on ice. Add the template RNA to
each tube containing the RT master mix. Incubate at 42 degrees C for 30 minutes to
increase cDNA yield and at 95 degrees C for 3 minutes to inactivate the enzyme.
Place the RT reactions on ice and perform RT PCR directly or store the reactions at 80 degrees.
Set up the RT-PCR reaction master mix according to the following recipe:
Taqman master mix, target 1 (GADPH) and target 2 (one of the genes we want to
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detect), ROX (for Roche master mix only), and nuclease-free water. Add 1× Taqman
master mix to a 384-well PCR plate, 4 ul per well, in triplicate for each assay. Add 1ul
of diluted cDNA to each well containing Taqman master mix. Seal the plate with
microseal film. Run QuanStudio real-time PCR using the comparative CT (Delta
Delta CT) method: 50°C for 2 min, 95°C for 10 sec, then 95°C for 15 sec, and 60°C
for 1 min for a total of 40 cycles. Analysis was performed using gene expression
format.
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3. Results

3.1 Culture outcomes
Most of our samples of wild type started contracting on Day 3-5 after printing
while the mixed type trend started contracting later than the wild type, usually on Day
5-7 after printing. There was also a contract area difference between the two groups,
the samples in the wild type usually had a greater contract area (Fig.12) than those in
the mixed type (Fig.13). Moreover, the samples in the wild type contracted as a whole
while onlwy a partial area of the samples in the mixed type contracted.
The comparison between the Fig.12 and Fig.13 images shows that the cells in
the wild type were more tightly connected to each other, while in the mixed type of
construct there is significantly smaller and less tissue formed by cell connections.
There were many tiny black dots in the areas of the mixed type of samples that were
not connected, and we suspected that these were apoptotic cells, but we did not
measure the cell survival rate. We plan to include survival measurements in our next
experiments.
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Fig.12 The figure shows the construct from wild type under a 40× microscope,
the photo was taken 20 days after printing, and the whole construct contracts
monolithically along the arrow direction.
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Fig.13 The image shows the culture of the mixed type at 20 days after
printing. The circle shows the contracted part of the construct visible in this area after
40× magnification.

3.2 Video analysis results
We chose the same parameters in our MATLAB program for all the videos we
wanted to analyze. We chose the 100× videos to do the measurements because they
have more detail than the 40× videos and a better field of view than the 200× videos.
Not all videos were analyzed, and we selected the samples with the longest culture
times, which had recordings of all time points.
The program was designed to calculate the pixel intensity changes for each
frame in the video. The intensity changes would be used to calculate the displacement
of the tissue in the video.
Our results are shown in Fig.14, where the maximal averaged displacement of
mixed type did not show a linear increase with culture time, reaching a maximum on
Day 10 then decreasing but increasing again on Day 25 (Fig.14(a)). In Fig.14(b), the
maximal averaged displacement of the wild type showed a slow increase with culture
time, with the maximum value occurring on Day 30, while at the first measurement
time (Day 5) the wild type showed a displacement close to the maximum value in the
mixed type. In the comparison between the two groups (Fig.14(c)), significant
differences were observed on Day 5, 20 and 30, wild type exhibits greater contraction
displacement.
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Fig.14 Comparison of the maximal averaged displacement of the two groups
of samples at different time points. (a) shows the mixed type, the displacement of this
group of samples did not increase gradually with the culture time, and the maximal
displacement appeared on Day 10. In (b), the displacement of the wild type reached
the maximum value of the mixed type on Day 5, and it did not increase sharply in the
next culture period but also increased slowly with time. (c) Comparison of the
displacements of the two groups of samples at different time points, showing
significant differences on Day 5, 20 and 30 (p<0.05).

The measurements of the maximal averaged contraction velocity for both
groups are shown in Fig.15. Since we kept the parameters the same when we shot the
video therefore the timestep of each frame of the video is the same 0.2 seconds. And
the way we calculate the contraction velocity was simply the displacement divided by
the time, so our results about the maximal contraction velocity are proportional to the
maximal displacement. Mixed type samples show a significant increase in contraction
velocity at the beginning of the culture, but a decrease at Day 15 and 20 and another
increase at Day 25. The wild type samples show a slow increase from the beginning to
the end of the culture. There is a significant difference between the two groups of
samples in the measurements on days 5, 20 and 30. Day 20 and 30 are both the time
points when the samples of the mixed type show a decrease in contraction velocity.
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Fig.15 Comparison of the maximal averaged velocity of the two groups of
samples at different time points. We used the same video specifications for filming
each frame of each video so the timesteps are consistent, the differences show here are
the same as Fig.14. The mixed type in (a) has no linear relationship with the maximal
velocity on Day 10. The wild type in (b) increases slowly with culture time, with the
maximum value at Day 30. In (c), the two groups of samples show significant
differences (p<0.05) on Days 5, 20 and 30.

3.3 Sarcomere length
The two groups of samples realized a huge difference after staining, where
sarcomeres were abundant and clearly visible in the wild type, but very few and faint
in the mixed type. Even in the early mixed samples, sarcomere was not found at all,
so it led us to not have enough data. In Fig.16, we show two samples on Day 20 after
fluorescence staining, (a) the sample of wild type and (b) the sample of mixed type,
and the difference is obvious. In (a), the wild type shows sufficient sarcomeres and is
very clear and has some alignment. In (b) it is difficult to find sarcomeres, which are
hidden in a cell and are not only very faint but also scarce.
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Fig.16 Pictures of sarcomeres observed under a 630× confocal microscope
after fluorescence staining of the samples on the Day 20 after printing. Comparing the
wild type (a) with the mixed type (b), we can easily see that there is a significant
difference in sarcomere clarity and alignment between the two. In (b), the sarcomeres
of the mixed type show only a few faint strips in one cell, while the sarcomeres of the
wild type in (a) are not only numerous but also very clear and has alignment.

The mixed type has the minimum sarcomere length on Day 5 and the maximal
length on Day 10 (Fig.17 (a)). The maximal length is 1.63 μm, corresponding to the
length of early sarcomere length of 1.6 μm in other studies (Lundy et al., 2013; Yang
et al., 2014). After Day 10, the sarcomere length decreased but was still higher than
the value on Day 5. Measurements of the mixed type were more difficult than those of
the wild type because it was difficult to observe clear sarcomeres in the early samples
of the mixed type than in the wild type, and because we collected only two samples at
each time point, there were insufficient data because sarcomeres were not observed in
some samples. Also, we did not have data for Day 30 because our samples were
contaminated before Day 30 and no clear sarcomere was observed in the collected
samples.
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The wild type shows a linear increase in sarcomere length, with significant
differences between Day 5 and other time points (Fig.17 (b)). After Day 5, the wild
type shows no significant differences in sarcomere length. The maximal sarcomere
length appears on Day 30 as 1.99 µm, which is close to the length of mature
sarcomeres mentioned in other studies of about 2 µm (Lundy et al., 2013; Yang et al.,
2014). In the comparison of the two data sets (Fig.17 (c)), only a significant
difference is observed on Day 20.

Fig.17 Comparison of the sarcomere lengths of the two groups of samples at
different time points. (a) The mixed type is shown to have the maximal sarcomere
length on Day 10, with a maximum value of about 1.6 μm. (b) The sarcomere length
of the wild type has a slow increase with time, with the maximum value occurring on
Day 30 and being about 2 μm. The sarcomere length on Day 5 shows significant
differences from other time points (p<0.05). In the comparison of the two groups of
samples (c), since we did not have enough data for the mixed type, we could only find
a significant difference between the two groups on Day 20 (p<0.05).

3.4 Organization index
The sample of the mixed type has data for only three time points (one at each
time point) due to insufficient sample, with the maximum value occurring on Day 10
and the minimal value on Day 20 (Fig.18 (a)) while the samples of the wild type show
a linear increase at the first three time points, but a small decrease at the last time

36

point. The maximum value appears on Day 20 and the minimal value on Day 5
(Fig.18 (b)). The mixed type does show a lower average organization index at each
time point, but additional samples are needed to confirm the observation (Fig.18 (c)).
Reviewing the measurements of maximal displacement and velocity and
sarcomere length, there is some consistency across time points for all measurements
in the wild type. Specifically, there is an increasing trend in the first 30 days, with a
significant difference in wild type sarcomere length between Day 5 and Day 10, 20
and 30, which is not reflected in the results for maximal displacement and velocity of
contraction.
The mixed type shows a maximum in displacement, velocity, and sarcomere
length results on Day 10, follows by a decrease in all measurements, reaching the first
underestimation of its growth phase at Day 20. It is reasonable to assume that the
mixed type has 50% of cardiomyocytes with HLHS and that these cells stop growing
or even show apoptosis after 20 days of culture, which leads to a decrease in the
upward trend that should occur in the growth phase of the whole construct.

Fig.18 Comparison of the organization index of the two groups of samples at
different time points. All sarcomere organization indices were normalized to the
highest recorded value, such that the reported tissue index is a value between 0 and 1.
The sarcomeres of mixed type (a) have the maximum value on Day 10. The wild type
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in (b) increases slowly with time but decreases on Day 30, so the maximum value
occurs at day 20. In (c) we were not able to show whether there is a significant
difference between the two groups because we did not have enough data on the mixed
type.

3.5 Wild type grows faster than mixed type
Gene expression in both sets of samples showed significant differences
between conventional 2D culture compared to the combination of 3D printing and 3D
cell culture, as well as dramatic differences between wild type and mixed type after
the same printing and culture.
It is important to note that since the 2D samples did not undergo the printing
step, the post-differentiation times are used uniformly in all subsequent comparisons
that include 2D samples. Another point to note is that the 2D samples do not have a
mixed type, but a variant type instead. The difference between the two is that the
mixed type contains half of the diseased cardiomyocytes and the normal healthy
cardiomyocytes, whereas the variant type contains only diseased cardiomyocytes.
ACTA1 is responsible for encoding skeletal muscle α-actin, which plays a
crucial role in muscle movement and contraction(Laing et al., 2009). But ACTA1
tends to be abundantly expressed in humans early in embryonic development, declines
in mid-to-late development and reaches negligible levels by the time the infant is born
(Ilkovski et al., 2005). As seen in Fig.19, the samples are stressed after 3D printing
and express higher ACTA1 levels, but this level becomes normal over time.
Comparing the wild type (3D wild type Day 16 was used as control) and mixed type
in 3D it is not difficult to find that the decrease of ACTA1 from Day 16 to Day 20
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(after differentiation) in the wild type is much higher than that in the mixed type, and
we speculate that the wild type has a faster developmental rate than the mixed type.
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Fig.19 Comparison of ACTA1 expression in 2D and 3D samples at different
time points. ACTA1 is abundantly expressed at the early stage of cardiomyocyte
development and gradually decreases with development. In the figure, it can be seen
that the decreasing trend of ACTA1 is more obvious in 3D wild type than 3D mixed
type, which indicates that wild type develops more rapidly than mixed type.

MYL2 has an important role in cardiac contractile function during early
embryonic development (Sheikh et al., 2015). The expression of 3D printed and
cultured wild type gradually increases over time (Fig.20), suggesting that 3D printed

39

cardiomyocytes have a more rapid maturation rate and cardiomyocytes are developing
from atrial like to ventricular like.

MYL2
150
118.960

RQ

100

46.477

50

1.329

3D mixed type Day 20

2.739

2.240

2D variant type Day 24

0.340

3D mixed type Day 16

3.011
1.000

2D wild type Day 24

13.801

3D wild type Day 45

3D wild type Day 35

3D wild type Day 25

3D wild type Day 20

3D wild type Day 16

0

Sample

Fig.20 Comparison of MYL2 expression in 2D and 3D samples at different
time points. The expression of MYL2 in the 3D wild type increases rapidly with
culture time, showing that the wild type has a faster maturation rate than the 3D
mixed type, and the cardiomyocytes are developing from atrial to ventricular shape.

SLN expression determines muscle relaxation function (Tupling et al., 2011),
but overexpression of SLN leads to reduced contractility in cardiomyocytes (Babu et
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al., 2005), so the expression of SLN decreases gradually with developmental time. The
mean value of SLN expression in 3D wild type shows a decrease, but the variance is
high, more samples are needed to improve that expression of SLN would decrease
from the early development in the 3D wild type. The 3D mixed type shows an
increased SLN expression even after 5 days of culture and there is a gradually
decreased SLN expression after Day 20 in wild type (Fig.21). Therefore, we speculate
that the wild type has a stronger contraction capacity than the mixed type.
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Fig.21 Comparison of SLN expression in 2D and 3D samples at different time
points. The expression of SLN decreases gradually with cell development, and it
determines the contractile ability of cardiomyocytes. SLN decreases gradually with
culture time in 3D wild type but increases in 3D mixed type. Based on this, we
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speculate that wild type has a stronger contractile capacity than mixed type. And more
samples are needed to confirm this.

BIN1 is a tumor suppressor protein (Sakamuro et al., 1996), from our results
(Fig.22) it appears that 3D printing do not have a dramatic effect on the expression of
BIN1.
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Fig.22 Comparison of BIN1 expression in 2D and 3D samples at different time
points. 3D printing does not have a significant effect on BIN1 expression.
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JPH2 plays a key role in promoting intracellular calcium release and cardiac
contraction (Landstrom et al., 2007). In Fig.23, the 3D printed samples express much
higher levels than the 2D samples, and there is also a large difference between the
wild type and the mixed type. There is a significant difference (p<0.05) between Day
16 and Day 20 in the 3D wild type, but not in the mixed type, showing that 3D wild
type has a faster developmental rate. Studies have shown that hypertrophic
cardiomyopathy is associated with downregulation of JPH2 (Landstrom et al., 2011) .
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Fig.23 Comparison of JPH2 expression in 2D and 3D samples at different
time points. 3D wild type has higher JPH2 expression level than mixed type,
suggesting that 3D treatment can promote the maturation of wild type, and
hypertrophic cardiomyopathy is also associated with the downregulation of this gene.
The significant difference (p<0.05) between Day 16 and Day 20 shows that 3D wild
type has a faster developmental rate.

KCNJ4 is associated with potassium channels (Li et al.), and it can be seen
from Fig.24 that the 3D wild type has much higher expression than the mixed type
and 2D samples, which indicates that the 3D wild type samples are more mature.
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Fig.24 Comparison of KCNJ4 expression in 2D and 3D samples at different
time points. The expression of KCNJ4 marks the maturity of cell development, and
the expression of KCNJ4 is much higher in 3D wild type than in mixed type,
indicating that wild type has higher cell maturity.

MYH6 is associated with the formation of myosin. In Fig.25, we can see that
there is a significant difference between Day 16 and Day 20 for the 3D wild type and
another significant difference between Day 20 for the 3D wild type and Day 20 for
the 3D mixed type, indicating that the 3D wild type rapidly expresses MYH6 and
therefore it is easy to see clearer sarcomeres in the 3D wild type samples. MYH6 has

45

been shown to be significantly associated with HLHS (Kim et al., 2020; TomitaMitchell et al., 2016). In our results 3D mixed type exhibits much lower MYH6
expression than healthy cells, demonstrating that mixed type contains a large number
of cardiomyocytes with HLHS.
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Fig.25 Comparison of MYH6 expression in 2D and 3D samples at different
time points. MYH6 is responsible for encoding myosin, the significant difference
between 3D wild type Day 16 and Day 20 shows that the 3D wild type has a more
rapid developmental rate. The significant difference (p<0.0005) of the expression of
MYH6 between the 3D wild and the 3D mixed type suggesting that the samples in the
3D wild type have a clearer sarcomere structure. It is also demonstrated that the 3D
mixed type contains cardiomyocytes with HLHS.
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MYH7 plays an important role in the contraction of the heart, and the 3D
samples shows higher MYH7 expression levels (Fig.26), while the wild type in the 3D
samples shows an increase compared with the mixed type, indicating that the wild
type has a contractile advantage over the mixed type. It also shows that the wild type
is more mature and ventricular like than the mixed type.
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Fig.26 Comparison of MYH7 expression in 2D and 3D samples at different
time points. MYH7 expression is associated with the contractility of cardiomyocytes.
3D wild type samples have higher MYH7 expression than 3D mixed type, indicating
that the wild type is more mature and contractile.
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MYL7 is mainly responsible for regulating cardiac development and
contractility, and the wild type in 3D samples has higher MYL7 expression levels than
the mixed type (Fig.27), suggesting that the wild type is more mature and more
contractile. It is also reported that downregulation of MYL7 is associated with
structural changes in the heart (Sun et al., 2022).
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Fig.27 Comparison of MYL7 expression in 2D and 3D samples at different
time points. The expression of MYL7 shows that the 3D wild type is more mature and
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contractile, and the downregulation of this gene is also associated with structural
changes in the heart.
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4. Discussion
According to a statistic from 2010-2014, 1353 out of 10,000 babies
investigated by researchers had HLHS (Mai et al., 2019). HLHS is congenital heart
disease with a high mortality rate, and even after staged surgery, it does not have a
100% survival rate and is associated with a variety of morbidities that undoubtedly
have multiple adverse effects on the patient. Research is increasingly looking for new
treatments for HLHS, but both drugs and gene editing require the creation of tissue
models (Wang et al., 2018b) that represent the structural and functional features of the
heart.
The first step in constructing a tissue model in vitro is cell culture, which is
traditionally done in 2D. However, almost all cells in the human body are surrounded
by other cells and extracellular matrix (ECM) in a three-dimensional (3D) manner
(Edmondson et al., 2014b), so in our study if we also cultured cardiomyocytes in 2D,
these cells tended to adhere to the plate resulting in failure to form 3D structures
(Duval et al., 2017b).
Also, the laminin in our bioink is the most powerful ECM enhancer for
cardiomyocyte maturation (Chanthra et al., 2020), and laminin can promote
cardiomyocyte alignment and enhance cardiomyocyte contractility (Mcdevitt et al.,
2002; Ribeiro et al., 2014).
The major difference between our culture method and traditional 2D culture is
crosslinking. We use UV light irradiation and crosslinking agent immersion to achieve
a perfect crosslinking effect, allowing our samples to be suspended in the culture
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medium. This allows each cell in the print to be immersed in the culture medium,
creating growth conditions that fully mimic the in vivo environment.
The 3D printing technology allows for the precise layer-by-layer placement of
bioink containing cells to create complex composite tissue structures. Each cell can be
in an in vivo-like growth environment surrounded by other cells and ECM.
Through our study we found that bioengineered tissue models printed from
iPSC-CMs were able to reproduce the activity of cardiomyocytes well in vitro.
Samples in the wild type usually show regional contraction within 2-4 days after
printing i.e., only a portion of the bioprinted tissue contracts. This contraction is very
visible and can be observed with the naked eye (Fig.28). Most of the samples will
gradually change from regional to global contraction (the printed tissue contracts as a
whole) during subsequent culture (approximately 5-8 days after printing). Compared
to the wild type, the mixed type tends to require a longer culture time (3-5 days)
before regional contraction is observed. At the same time, samples in the mixed type
tend not to show global contraction.
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Fig.28 A frame from a video of a printed-out wild construct contraction taken
with a cell phone (3× magnification).

Since the video analysis program we use is used to determine the maximal
averaged displacement for each frame in the video, i.e., the displacement of each pixel
is added together and then averaged for each pixel. Integral contraction produces a
larger range of displacement, so samples in the wild type tend to have a larger
displacement than the mixed type. This method does not reflect the experimental
variability, as we fixed the frame rate of the video shots, each at 5 frames per second,
with a timestep of 0.2 seconds. This resulted in the measurement of the contraction
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velocity obtaining almost the same results as the displacement, despite the different
displacements demonstrated for each sample, due to the step length limitation. We
would like to point out that the results for displacement are more reliable than those
for velocity. This method does not actually calculate the contraction velocity produced
by the complete contraction, but we did not find a method that could achieve this
calculation with automation, which is one of the goals of our subsequent research.
Both sarcomere length and organization index are the criteria we used to judge
the maturity of our samples. In the results of sarcomere length, it can be seen that the
wild type grows rapidly until Day 10, then slows down and reaches a maximum on
Day 30. The mixed type also has a rapid growth rate until Day 10 but starts to decline
after Day 10. Combined with the maximal displacement we calculated, the results of
these two analyses are very consistent. Therefore, we hypothesize that at about 10
days after printing (approximately 25 days after differentiation) the cardiomyocytes
with disease reach their maximal development, while the healthy cells have a longer
developmental time.
In our study, organization index was used as another indicator to determine the
degree of development of cardiomyocytes and alignment. It is higher in wild type than
in mixed type for the same culture time. Mixed type reaches a maximum on Day 10
and then decreases, in agreement with our previous results for maximal displacement,
maximal velocity and sarcomere length. The maximum value of the wild type is
reached on Day 20 and decreases slightly on Day 30, in agreement with the previous
analysis.
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The RT-qPCR results show that the cells looked more mature (JPH2, MYH7,
KCNJ4) and ventricle-like (MYL2, MYH7) in the 3D printed samples, and there are
also significant differences between the wild type and the mixed type. In general, the
RT-qPCR results are consistent with previous measurements, and the 3D processed
samples has the advantages of faster development and greater contractility than the
conventional 2D samples. They also show the difference in gene expression between
healthy and diseased donors, a feature that is important for future research on
effective treatment of HLHS.
Also, we found that the expression level of MYH6 in mixed type at Day 16 is
about half of that in wild type, which is consistent with the fact that we had only half
of the healthy cardiomyocytes of wild type in mixed type at the time of cell
preparation. However, the difference in expression levels between the two groups
widens dramatically on Day 5, and no longer shows the relationship that the mixed
type is half of the wild type. Our hypothesis is that the diseased cardiomyocytes in the
mixed type are damaging the healthy cells and disrupting the protein expression so
that the healthy half of the cardiomyocytes do not express at the level they should. A
similar situation occurs with the expression of JPH2.
Although our study successfully showed the difference between healthy and
disease-carrying cardiomyocytes in vitro culture, we have many shortcomings, such
as the number of samples is too small, the sample culture time is not long enough, and
the method of analyzing data is not comprehensive enough. We measured the length
of wild type cardiomyocytes to be more than 100 μm, corresponding to 100 to 150 μm
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in other studies. However, we did not measure the length of cardiomyocytes in the
mixed type because it was difficult to find well-structured sarcomeres in the mixed
type. Also, we did not measure the heart rate of the printed heart tissue, which is an
important indicator to compare the difference between healthy and disease-carrying,
and we will include it in the subsequent experiments. We will continue to modify our
protocol and add other tests such as drug tests in subsequent studies to make this
model more informative.
The innovation and importance of our study is to simulate the growth
environment of cardiomyocytes in the human body, substantially eliminating the
differences caused by external factors such as culture and reflecting only the
differences between healthy and diseased cardiomyocytes themselves.
These differences are the expression of the differences between healthy people
and HLHS patients. If we can improve the performance of the disease-carrying model
by some medical means, perhaps we can apply the same approach to the treatment of
patients. But we still have a long way to go before we can achieve this. We want to
eliminate the differences in external factors, but we don't know if there are other
factors besides the culture environment. Also, we may be able to improve the
performance of disease-carrying cardiomyocytes in in vitro culture, but we have no
way of knowing if the same means are applicable to humans.
Although there is still a long way to go between the establishment of a
differential model and the discovery of a treatment, we have made a good foundation
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for other researchers, and we hope that someday in the future someone will be able to
refine the treatment of HLHS based on our model and bring it to patients.
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5. Conclusion
Our study succeeded in building a model in vitro that can mimic the growth
environment of cardiomyocytes in vivo, a model with the functional characterization
and gene expression of cardiomyocytes and able to show the difference between
healthy and disease-carrying cardiomyocytes. We hope that our research will inspire
more scholars and bring more attention to the importance of 3D bioprinting in
research and medicine and that we will continue to improve our less-than-perfect
model so that this model can be a helpful tool in the future to study the treatment of
patients with HLHS.

57

BIBLIOGRAPHY

[1] Barron DJ, Kilby MD, Davies B, Wright JG, Jones TJ, Brawn WJ. Hypoplastic
left heart syndrome. Lancet. 2009 Aug 15;374(9689):551-64. doi:
10.1016/S0140-6736(09)60563-8. PMID: 19683641.
[2] Best KE, Miller N, Draper E, Tucker D, Luyt K, Rankin J. The Improved
Prognosis of Hypoplastic Left Heart: A Population-Based Register Study of 343
Cases in England and Wales. Front Pediatr. 2021 Jul 6;9:635776. doi:
10.3389/fped.2021.635776. PMID: 34295856; PMCID: PMC8289898.
[3] Tabbutt S, Dominguez TE, Ravishankar C, Marino BS, Gruber PJ, Wernovsky G,
Gaynor JW, Nicolson SC, Spray TL. Outcomes after the stage I reconstruction
comparing the right ventricular to pulmonary artery conduit with the modified
Blalock Taussig shunt. Ann Thorac Surg. 2005 Nov;80(5):1582-90; discussion
1590-1. doi: 10.1016/j.athoracsur.2005.04.046. PMID: 16242421.
[4] Feinstein JA, Benson DW, Dubin AM, Cohen MS, Maxey DM, Mahle WT, Pahl
E, Villafañe J, Bhatt AB, Peng LF, Johnson BA, Marsden AL, Daniels CJ, Rudd
NA, Caldarone CA, Mussatto KA, Morales DL, Ivy DD, Gaynor JW, Tweddell
JS, Deal BJ, Furck AK, Rosenthal GL, Ohye RG, Ghanayem NS, Cheatham JP,
Tworetzky W, Martin GR. Hypoplastic left heart syndrome: current
considerations and expectations. J Am Coll Cardiol. 2012 Jan 3;59(1 Suppl):S142. doi: 10.1016/j.jacc.2011.09.022. Erratum in: J Am Coll Cardiol. 2012 Jan
31;59(5):544. PMID: 22192720; PMCID: PMC6110391.
[5] Wang Z, Lee SJ, Cheng HJ, Yoo JJ, Atala A. 3D bioprinted functional and
contractile cardiac tissue constructs. Acta Biomater. 2018 Apr 1;70:48-56. doi:
10.1016/j.actbio.2018.02.007. Epub 2018 Feb 13. PMID: 29452273; PMCID:
PMC6022829.
[6] Park, IH., Lerou, P., Zhao, R. et al. Generation of human-induced pluripotent stem
cells. Nat Protoc 3, 1180–1186 (2008). https://doi.org/10.1038/nprot.2008.92
[7] Karakikes I, Ameen M, Termglinchan V, Wu JC. Human induced pluripotent stem
cell-derived cardiomyocytes: insights into molecular, cellular, and functional
phenotypes. Circ Res. 2015 Jun 19;117(1):80-8. doi:
10.1161/CIRCRESAHA.117.305365. PMID: 26089365; PMCID:
PMC4546707.
[8] Jiang Y, Habibollah S, Tilgner K, Collin J, Barta T, Al-Aama JY, Tesarov L,
Hussain R, Trafford AW, Kirkwood G, Sernagor E, Eleftheriou CG, Przyborski
S, Stojković M, Lako M, Keavney B, Armstrong L. An induced pluripotent stem
cell model of hypoplastic left heart syndrome (HLHS) reveals multiple
expression and functional differences in HLHS-derived cardiac myocytes. Stem

58

Cells Transl Med. 2014 Apr;3(4):416-23. doi: 10.5966/sctm.2013-0105. Epub
2014 Mar 3. PMID: 24591732; PMCID: PMC3973710.
[9] Edmondson R, Broglie JJ, Adcock AF, Yang L. Three-dimensional cell culture
systems and their applications in drug discovery and cell-based biosensors.
Assay Drug Dev Technol. 2014 May;12(4):207-18. doi: 10.1089/adt.2014.573.
PMID: 24831787; PMCID: PMC4026212.
[10] Duval K, Grover H, Han LH, Mou Y, Pegoraro AF, Fredberg J, Chen Z.
Modeling Physiological Events in 2D vs. 3D Cell Culture. Physiology
(Bethesda). 2017 Jul;32(4):266-277. doi: 10.1152/physiol.00036.2016. PMID:
28615311; PMCID: PMC5545611.
[11] Murphy SV, Atala A. 3D bioprinting of tissues and organs. Nat Biotechnol. 2014
Aug;32(8):773-85. doi: 10.1038/nbt.2958. PMID: 25093879.
[12] Ozbolat IT, Hospodiuk M. Current advances and future perspectives in extrusionbased bioprinting. Biomaterials. 2016 Jan;76:321-43. doi:
10.1016/j.biomaterials.2015.10.076. Epub 2015 Oct 31. PMID: 26561931.
[13] GhavamiNejad A, Ashammakhi N, Wu XY, Khademhosseini A. Crosslinking
Strategies for 3D Bioprinting of Polymeric Hydrogels. Small. 2020
Sep;16(35):e2002931. doi: 10.1002/smll.202002931. Epub 2020 Jul 30. PMID:
32734720; PMCID: PMC7754762.
[14] Reddy N, Reddy R, Jiang Q. Crosslinking biopolymers for biomedical
applications. Trends Biotechnol. 2015 Jun;33(6):362-9. doi:
10.1016/j.tibtech.2015.03.008. Epub 2015 Apr 14. PMID: 25887334.
[15] Derakhshanfar S, Mbeleck R, Xu K, Zhang X, Zhong W, Xing M. 3D bioprinting
for biomedical devices and tissue engineering: A review of recent trends and
advances. Bioact Mater. 2018 Feb 20;3(2):144-156. doi:
10.1016/j.bioactmat.2017.11.008. PMID: 29744452; PMCID: PMC5935777.
[16] Gao, G., Lee, J. H., Jang, J., Lee, D. H., Kong, J.-S., Kim, B. S., Choi, Y.J., Jang, W. B., Hong, Y. J., Kwon, S.-M., Cho, D.-W., Adv. Funct.
Mater. 2017, 27, 1700798. https://doi.org/10.1002/adfm.201700798
[17] Lian X, Bao X, Zilberter M, Westman M, Fisahn A, Hsiao C, Hazeltine LB,
Dunn KK, Kamp TJ, Palecek SP. Chemically defined, albumin-free human
cardiomyocyte generation. Nat Methods. 2015 Jul;12(7):595-6. doi:
10.1038/nmeth.3448. PMID: 26125590; PMCID: PMC4663075.
[18] Shradhanjali A, Riehl BD, Duan B, Yang R, Lim JY. Spatiotemporal
Characterizations of Spontaneously Beating Cardiomyocytes with Adaptive
Reference Digital Image Correlation. Sci Rep. 2019 Dec 5;9(1):18382. doi:
10.1038/s41598-019-54768-w. PMID: 31804542; PMCID: PMC6895104.
[19] Hinson JT, Chopra A, Nafissi N, Polacheck WJ, Benson CC, Swist S, Gorham J,
Yang L, Schafer S, Sheng CC, Haghighi A, Homsy J, Hubner N, Church G,

59

Cook SA, Linke WA, Chen CS, Seidman JG, Seidman CE. HEART DISEASE.
Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated
cardiomyopathy. Science. 2015 Aug 28;349(6251):982-6. doi:
10.1126/science.aaa5458. PMID: 26315439; PMCID: PMC4618316.
[20] Deacon DC, Happe CL, Chen C, Tedeschi N, Manso AM, Li T, Dalton ND, Peng
Q, Farah EN, Gu Y, Tenerelli KP, Tran VD, Chen J, Peterson KL, Schork NJ,
Adler ED, Engler AJ, Ross RS, Chi NC. Combinatorial interactions of genetic
variants in human cardiomyopathy. Nat Biomed Eng. 2019 Feb;3(2):147-157.
doi: 10.1038/s41551-019-0348-9. Epub 2019 Feb 7. PMID: 30923642; PMCID:
PMC6433174.
[21] Lundy SD, Zhu WZ, Regnier M, Laflamme MA. Structural and functional
maturation of cardiomyocytes derived from human pluripotent stem cells. Stem
Cells Dev. 2013 Jul 15;22(14):1991-2002. doi: 10.1089/scd.2012.0490. Epub
2013 Apr 5. PMID: 23461462; PMCID: PMC3699903.
[22] Yang X, Pabon L, Murry CE. Engineering adolescence: maturation of human
pluripotent stem cell-derived cardiomyocytes. Circ Res. 2014 Jan
31;114(3):511-23. doi: 10.1161/CIRCRESAHA.114.300558. PMID: 24481842;
PMCID: PMC3955370.
[23] Laing, Nigel G et al. “Mutations and polymorphisms of the skeletal muscle
alpha-actin gene (ACTA1).” Human mutation vol. 30,9 (2009): 1267-77.
doi:10.1002/humu.21059
[24] Ilkovski B, Clement S, Sewry C, North KN, Cooper ST. Defining alpha-skeletal
and alpha-cardiac actin expression in human heart and skeletal muscle explains
the absence of cardiac involvement in ACTA1 nemaline myopathy. Neuromuscul
Disord. 2005 Dec;15(12):829-35. doi: 10.1016/j.nmd.2005.08.004. Epub 2005
Nov 8. PMID: 16288873.
[25] Sheikh F, Lyon RC, Chen J. Functions of myosin light chain-2 (MYL2) in
cardiac muscle and disease. Gene. 2015 Sep 10;569(1):14-20. doi:
10.1016/j.gene.2015.06.027. Epub 2015 Jun 12. Erratum in: Gene. 2015 Oct
15;571(1):151. PMID: 26074085; PMCID: PMC4496279.
[26] Tupling AR, Bombardier E, Gupta SC, Hussain D, Vigna C, Bloemberg D,
Quadrilatero J, Trivieri MG, Babu GJ, Backx PH, Periasamy M, MacLennan
DH, Gramolini AO. Enhanced Ca2+ transport and muscle relaxation in skeletal
muscle from sarcolipin-null mice. Am J Physiol Cell Physiol. 2011
Oct;301(4):C841-9. doi: 10.1152/ajpcell.00409.2010. Epub 2011 Jun 22. PMID:
21697544; PMCID: PMC3654932.
[27] Babu GJ, Zheng Z, Natarajan P, Wheeler D, Janssen PM, Periasamy M.
Overexpression of sarcolipin decreases myocyte contractility and calcium
transient. Cardiovasc Res. 2005 Jan 1;65(1):177-86. doi:
10.1016/j.cardiores.2004.08.012. PMID: 15621045.

60

[28] Sakamuro D, Elliott KJ, Wechsler-Reya R, Prendergast GC. BIN1 is a novel
MYC-interacting protein with features of a tumour suppressor. Nat Genet. 1996
Sep;14(1):69-77. doi: 10.1038/ng0996-69. PMID: 8782822.
[29] Landstrom AP, Weisleder N, Batalden KB, Bos JM, Tester DJ, Ommen SR,
Wehrens XH, Claycomb WC, Ko JK, Hwang M, Pan Z, Ma J, Ackerman MJ.
Mutations in JPH2-encoded junctophilin-2 associated with hypertrophic
cardiomyopathy in humans. J Mol Cell Cardiol. 2007 Jun;42(6):1026-35. doi:
10.1016/j.yjmcc.2007.04.006. Epub 2007 Apr 18. PMID: 17509612; PMCID:
PMC4318564.
[30] Landstrom AP, Kellen CA, Dixit SS, van Oort RJ, Garbino A, Weisleder N, Ma J,
Wehrens XH, Ackerman MJ. Junctophilin-2 expression silencing causes
cardiocyte hypertrophy and abnormal intracellular calcium-handling. Circ Heart
Fail. 2011 Mar;4(2):214-23. doi: 10.1161/CIRCHEARTFAILURE.110.958694.
Epub 2011 Jan 7. PMID: 21216834; PMCID: PMC3059380.
[31] Li, Tao, et al. "Screening of potassium channel mutations in patients with atrial
fibrillation."
[32] Kim MS, Fleres B, Lovett J, Anfinson M, Samudrala SSK, Kelly LJ, Teigen LE,
Cavanaugh M, Marquez M, Geurts AM, Lough JW, Mitchell ME, Fitts RH,
Tomita-Mitchell A. Contractility of Induced Pluripotent Stem CellCardiomyocytes With an MYH6 Head Domain Variant Associated With
Hypoplastic Left Heart Syndrome. Front Cell Dev Biol. 2020 Jun 23;8:440. doi:
10.3389/fcell.2020.00440. PMID: 32656206; PMCID: PMC7324479.
[33] Tomita-Mitchell A, Stamm KD, Mahnke DK, Kim MS, Hidestrand PM, Liang
HL, Goetsch MA, Hidestrand M, Simpson P, Pelech AN, Tweddell JS, Benson
DW, Lough JW, Mitchell ME. Impact of MYH6 variants in hypoplastic left heart
syndrome. Physiol Genomics. 2016 Dec 1;48(12):912-921. doi:
10.1152/physiolgenomics.00091.2016. Epub 2016 Oct 27. PMID: 27789736;
PMCID: PMC5206387.
[34] Sun J, Guo X, Yu P, Liang J, Mo Z, Zhang M, Yang L, Huang X, Hu B, Liu J,
Ouyang Y, He M. Vasorin deficiency leads to cardiac hypertrophy by targeting
MYL7 in young mice. J Cell Mol Med. 2022 Jan;26(1):88-98. doi:
10.1111/jcmm.17034. Epub 2021 Dec 2. PMID: 34854218; PMCID:
PMC8742182.
[35] Mai CT, Isenburg JL, Canfield MA, Meyer RE, Correa A, Alverson CJ, Lupo PJ,
Riehle-Colarusso T, Cho SJ, Aggarwal D, Kirby RS; National Birth Defects
Prevention Network. National population-based estimates for major birth
defects, 2010-2014. Birth Defects Res. 2019 Nov 1;111(18):1420-1435. doi:
10.1002/bdr2.1589. Epub 2019 Oct 3. PMID: 31580536; PMCID:
PMC7203968.

61

[36] Wang Z, Lee SJ, Cheng HJ, Yoo JJ, Atala A. 3D bioprinted functional and
contractile cardiac tissue constructs. Acta Biomater. 2018 Apr 1;70:48-56. doi:
10.1016/j.actbio.2018.02.007. Epub 2018 Feb 13. PMID: 29452273; PMCID:
PMC6022829.
[37] Edmondson R, Broglie JJ, Adcock AF, Yang L. Three-dimensional cell culture
systems and their applications in drug discovery and cell-based biosensors.
Assay Drug Dev Technol. 2014 May;12(4):207-18. doi: 10.1089/adt.2014.573.
PMID: 24831787; PMCID: PMC4026212.
[38] Duval K, Grover H, Han LH, Mou Y, Pegoraro AF, Fredberg J, Chen Z.
Modeling Physiological Events in 2D vs. 3D Cell Culture. Physiology
(Bethesda). 2017 Jul;32(4):266-277. doi: 10.1152/physiol.00036.2016. PMID:
28615311; PMCID: PMC5545611.
[39] Chanthra N, Abe T, Miyamoto M, Sekiguchi K, Kwon C, Hanazono Y, Uosaki H.
A Novel Fluorescent Reporter System Identifies Laminin-511/521 as Potent
Regulators of Cardiomyocyte Maturation. Sci Rep. 2020 Mar 6;10(1):4249. doi:
10.1038/s41598-020-61163-3. PMID: 32144297; PMCID: PMC7060274.
[40] McDevitt TC, Angello JC, Whitney ML, Reinecke H, Hauschka SD, Murry CE,
Stayton PS. In vitro generation of differentiated cardiac myofibers on
micropatterned laminin surfaces. J Biomed Mater Res. 2002 Jun 5;60(3):472-9.
doi: 10.1002/jbm.1292. PMID: 11920672.
[41] Ribeiro AJ, Zaleta-Rivera K, Ashley EA, Pruitt BL. Stable, covalent attachment
of laminin to microposts improves the contractility of mouse neonatal
cardiomyocytes. ACS Appl Mater Interfaces. 2014 Sep 10;6(17):15516-26. doi:
10.1021/am5042324. Epub 2014 Aug 26. PMID: 25133578; PMCID:
PMC4160263.

62

APPENDIX
A. Preparation of bioink and cells
1. Preheat the beads, media, trypsin and bioink approximately 30 minutes
prior to start.
2. Aspirate the medium, add 1 ml of PBS solution to wash the cells then
aspirate the PBS solution.
3. Add 1 ml of 0.25% trypsin and incubate at 37 degrees C for 10 minutes.
4. The cells were separated in trypsin by several aspirations with a pipette.
5. Collect cells and add double amount of RPMI/20% FBS solution and mix
well by inverting tube.
6. Take 10ul and count the cells using a Biorad cell counter.
7. Centrifuge at 1000 rpm for 5 minutes.
8. During centrifugation, a blunt forceps is used to connect the syringe to the
tubing.
9. Take the ink warmed at 37 degrees, connect the syringe, push the ink tube
with blunt forceps and transfer 0.8 ml of ink to the syringe.
10. Take the centrifuged cells, aspirate the supernatant off and take the cell
pellet.
11. Resuspend the cells in 0.2 ml of medium.
12. Add 1μl of 5 μM Rock inhibitor to the cells.
13. Add the cells to bioink.
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14. Connect a new 3 ml syringe to the cell + bioink syringe and mix, pushing
the syringe back and forth 10 times to distribute the cells evenly in the ink.
15. Remove empty syringe.
16. Place the stopper in the syringe to be used for printing and connect it to the
syringe containing the cell and ink mixture and fill the new syringe with
ink + cells.
17. Seal the top and bottom of the syringe to be used for printing with the
caps.
18. Centrifuge the syringe at 1000 rpm for 5 minutes.
19. Remove excessive bubbles.
20. Put prepared ink+cells in the 37 degrees warmed up beads.
21. Before printing, the ink + cells are incubated at 25 degrees for 10 minutes
to cool down to the temperature required for printing.
B. Protocol for bioprinting
1. Turn on bioprinter.
2. Under Utilities menu, change printheads to 25°C.
3. Under Utilities menu, set airflow to 15.
4. Calibrate both pressure gauges by depressing both gray buttons on each
display simultaneously for a few seconds. Display will zero out.
5. Turn on compressor. Syringe holder should move up.
6. Set syringe #1 and syringe #2 pressure to zero using valves on right side of
printer. Pull out each knob, adjust and push back in to lock.
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7. Place calibration syringe into the holder and under Prepare Bioprinting on
main screen select Home Axes.
8. Syringe holder will pop down and locate the origin for printing.
9. Place waste plate and move z to +8.
10. Calibrate z.
11. Remove plate and calibration syringe.
12. Spray surface underneath printing tray thoroughly with 70% EtOH and
wipe clean.
13. Secure syringe in holder and make sure it is all the way down, place the
waste plate.
14. Under Prepare Bioprint, select Turn on Printhead 1 and slowly adjust
pressure until ink is flowing smoothly (around 18kPa).
15. Turn off Printhead 1.
16. Under main menu, Bioprint, select code (4×4×0.6mm) that was loaded for
the specific print job.
17. After the previous plate is printed, replace it with a new plate.
18. Remove syringe (with bioink and cells) and dispose of in biohazard.
19. Dial printhead pressures back to 0.
20. Turn off air compressor.
21. Press valve on back of compressor to release air.
22. Turn off bioprinter.
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23. All biohazards must be placed in biohazard trashcan. No open bags can be
left overnight for safety reasons.
24. Use cavicide to clean all surfaces inside the bioprinter.
25. Use cavicide to clean all lab bench surfaces surrounding bioprinter.
C. Protocol for immunofluorescence staining
1. Drain as much medium off as possible.
2. Gently rinse the 3D constructs at least 3 times with 1× PBS.
3. Fix the 3D constructs with 4% PFA and shake them at -4 degrees C for 15
minutes.
4. Wash with PBS 3 times.
5. Permeabilize with 0.2% Triton/PBS solution and shake for 15 minutes to
disrupt the membrane.
6. Remove Triton/PBS solution.
7. Apply the primary antibodies together in PBS overnight at the 4 degrees C
by rocking with following concentrations:
a. Apply GATA4 at a 1:400.
b. Apply α-actinin at a 1:250 dilution.
8. Remove the primary antibodies and rinse 4 times with PBS.
9. Apply the secondary antibodies together in PBS for 1 hour at room
temperature using a dilution for both of 1:750 and DAPI at the same
dilution:
a. Donkey anti-Rabbit Alexa Fluor 594.
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b. Goat anti-Mouse IgG1 Alexa Fluor 488.
c. DAPI.
10. Thoroughly wash out the secondary antibodies using 1x PBS.
11. Mount a coverslip over cells using Prolong Gold Antifade regent.
D. Protocol for organization index measurement
1. Select the image you want to measure the organization index, if it is a
multi-color image, you can separate the colors in ImageJ, the operation is
as follows: Image, Color, Split Channels, then Process, Binary, Make
Binary; if it is a single-color image, directly Image Type 8-bit, then
Process, Binary, Make Binary.
2. The processed image will be Analyze, Tools, Grid, you can freely choose
the size of Area per point, the default value is 51782 pixels2.
3. Select Straight Line in the toolbar and draw a straight line through the
sarcomeres along their alignment in the grid.
4. Use CTRL + K after drawing the line, get the intensity table.
5. Click Data, Copy All Data at the bottom of the table, then create a new
Text Document in the folder you like, and name it with a number, then
paste the copied data in it. For example, the TXT file named '1' contains
the data copied from the first grid, the TXT file named '2' contains the data
copied from the second grid, and so on.
6. After you have stored all the grid data in the TXT file, open MATLAB and
use the following code you will get the organization index of each grid.
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clear all
cd('C:\Users\Auster\Desktop\new\4.22 p2d10');% The location
where you store your data
for k=8:9;%The number of the TXT file you want to analyze
myfilename = sprintf('%d.txt', k);
mydata{k} = importdata(myfilename);
y_1 = cell2mat(mydata(k)); %Import Region of Interest
intensity .txt file
y = y_1.data;
y = mydata{1,k}.data(:,2);
z = fftshift(fft(y));
rawpowerspec=abs(z).^2;
powerspecnorm=(rawpowerspec)./(max(max(rawpowerspec)));
pks = findpeaks(powerspecnorm);
b = sort(pks);
c = length(b);
d(k) = b(c-1);
end

E. Protocol for sarcomere length measurement
1. Choose and open the image you want to measure in ImageJ.
2. Enlarge the scale bar, use the straight-line tool to draw a line from the
beginning to the end of the scale.
3. Click Analyze then Set Scale, fill in the actual length in the Known
distance, change the unit to the actual unit.
4. You will get a value in unit of pixels/μm, then you need to calculate the
length of each pixel.
5. Choose the same image you opened in ImageJ, then open it in ZEN
software.
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6. Select Profile in the left toolbar, then click Rectangle.
7. Enlarge the area of interest, use mouse to draw a rectangle perpendicular
to the sarcomeres.
8. You will get an intensity plot of the sarcomeres within the rectangle you
drew.
9. Measure the pixel distance between peaks.
10. Multiply the distance with the ratio you got from ImageJ.

